Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has ...

ChromaDex reports revenue growth with Niagen leading success, despite risks, its e-commerce surge and profits signal ...

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science ...

ChromaDex Corporation’s CDXC share price has dipped by 10.06%, which has investors questioning if this is right time to buy.

Q4 2024 Earnings Call Transcript March 4, 2025 ChromaDex Corporation beats earnings expectations. Reported EPS is $0.09, expectations were $0.02. Operator: Ladies and gentlemen, thank you for standing ...

It's also reported to have immense benefits for the skin too. We recommend the Tru Niagen Pro if you're seeking an ...

ChromaDex Corp (CDXC) reports a 37% revenue increase and a significant turnaround in net income, while addressing supply chain challenges and competitive pressures.

The company said, “For the full year 2025, the Company expects to build on the momentum established in 2024, projecting approximately 18% ...

Starting Wednesday, March 19, 2025, the company will operate under the new name Niagen Bioscience, Inc. and will be trading on the Nasdaq stock market with a new ticker symbol, NAGE. This change ...

NexGen Health in San Jose introduces Niagen Plus IV Therapy, an advanced treatment that boosts cellular health, enhances energy, and combats aging by replenishing NAD+ levels using nicotinamide ...

Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corporation's fourth quarter of 2024 earnings conference call. My name is Pia, and I will be your conference operator today.

It appears that the world is finally catching on to the importance of NAD and the fact that Niagen is the safest and most effective way to increase NAD levels, particularly in damaged cells.